AR and Familial prostate cancer: Initially, most prostate cancers are responsive to androgen deprivation therapy, but eventually, some will progress to a castration resistant state [2].These castration resistant prostate cancers (CRPC) require alternate approaches to treatment, which currently include traditional chemotherapeutics, newer androgen receptor antagonists, and a variety of immunotherapies [3].